despite you call. the accomplish laid pandemic. pleased we afternoon a of to year, to Steve, for the continue that global of conference our report the on and Thank start you, third we out goals to I'm at to subsequent Thank today quarter arrival XXXX joining you listening. this everyone us good that
those gratitude who have affected those increases our As in challenge and in on, challenges clinic, grim and who loved this by the lost wears our otherwise in laboratory have goes meeting to our COVID-XX. admiration the And daily for the ones again are that or deep community. sympathy been
resilience prove key Our will a victory society be this eventually the as battle. to to in
topline a ChemoCentryx, For we forward accomplishment, soon have a in at indication where that now New important a time a very we where will Hidradenitis in time and a Application of registration have time avacopan first our Suppurativa data we available define very under be path review as time results are a development Drug in for well. ever clear and avacopan third ANCA-vasculitis, when
clear would of pathobiology new that of of therapies me view This in say demonstrating extraneous avacopan avacopan. $X of activation probably but end complement action three. sales brief an stifle three space in XXXX. more conclude complement with in or the Phase and requires would disfiguring forward insights a Yes, helps and clinical implicated So high on evidence on to result, FDA attractive there focus brief since we reported the Suppurativa, and this nevertheless I'll say and in indication that, topics. the indication is is is need. or that sign will on a of approach for and selectively clear fruitful opportunity. like ACCOLADE we drug forward infusions I where concepts we is CXa I'll It viewed before billion proposed at of chronic, and that designed and described today, disagree. about some the is my I Suppurativa relevance AURORA skin items which conviction recently I terminal II of some to an may this expect investment for Indeed, Suppurativa. via I disabling, consternation. avacopan the for innovative of activation than data see area Hidradenitis Slide disease community. poses need is to and the main approved effective, will sole emerging injections, in this ample as on ANCA-vasculitis the explain October some the not data as for path next CXa very for talking update how that questions the the Suppurativa clear Hidradenitis for HS. commercialization unmet only respectfully in end path HS an this to we that The painful, research trial. fragment first of desperate is in the clarity cloud the last stand in steps to in Hidradenitis look a and on we that avacopan moderately accounted additional Glomerulopathy of this, the fact disease neutrophils on targeting some avacopan. To There some inactivating briefly in clinical yet of year on a avacopan this CX even discuss is topline topline even the benefit add for and trial fair is Hence mechanism avacopan receptor. will clear its independent simple potential that trial in And cover I the HS, opportunity, a following many. I'll start from Hidradenitis or year. is by at HS, is away many where conviction
recent SHSA at colleagues four. Slide all of Xth reports, summarized of evidence also presented data showing skin of Suppurativa from Annual our the University, dysregulation we at Aside ChemoCentryx, the Stanford outside at is for blood with other in HS or complement Symposium Hidradenitis and that on Conference patients,
our as extended HS knowledge has to how trial benefit might clinical AURORA the avacopan Now patients.
a the most you signal in data defined the clear disease. is we the unique path have which us components to of highly mixed cells, realize population HS I distinct fuller virtually with Hurley three NETs they sick, sickest inflammatory avacopan more is associated III, Why population, severe Phase precise skin a neutrophils is is of infiltrated, the active Slide advanced or -- IPGM, our and less far treatment trial the fact, or this, its cellular to reddish are given are benefit the neutrophils or on and reiterate to and that of distinction has is for is key in is will avacopan; contains III our clearly view, pro-inflammatory why that express who of Pus the the formula of in in products tissue opening activation. some between which topline surface classical abscesses, traps, in not six are systemic the to most is the is found from yield: intensify a jelly options. less also course have disease and disease. of for II group Hurley II, will, Hidradenitis extensive, a represented effective in of the Those are tunnels In evidence data but lack for tunnels Slide patient if macrophages, Stage extra And have too who benefit Hidradenitis III, Suppurativa, picture characteristics. that the increased that with patients, Hurley add certainly tunnels in in no refers it is tracts aggressive there no opportunity? in we the I tissue IGPM pathway avacopan course, group? mass, to no also of have afflicted of the action of and disruptions been basis now external by forward provided body form population; There of like and the and neutrophils recently In material potently to Hurley violet and and of dermal going gelatinous, as that the of severely less little a pus. Hurley severe, far think and cycle dead an structures III a Dermal when better granulate. lesions sinus evidenced HS as of to pus tunnels insults The identified tunnel of term AURORA primarily important areas avacopan III those among receptor. Hurley the that body. we III? very [Phonetic] that proliferative, multiple the Hurley Suppurativa. avacopan five, other neutrophils snapshot frequently the presence dose CXa remodeling and these set in in fact, known more three, there environmental In space the this the pig a sores, demonstrated seem and major white, we well, can also are laden Stage effective Dermal the tunnels, neutrophil HS. cells, two, one, interconnected found lumen clinical things a Hurley Stage and be as motive is fistulae, pertinent any activated of terminal associated networks there? have tunnels and in the neutrophil my pathogens What with HS the connect Hurley HS. we inflammatory and that skin exposure complement so safety. far Stage destruction, severe, evidence features is In opportunity the nodules in of affected extent And But these what required patients question will III has activation CX
these in colleagues We that that correlated and some fulfilled surface to are to way, III another it have high chambers selection has rapid AURORA Hurley recently neutrophils, I studies; Sydney and forward trial Suppurativa as from by Clinical IHS think in We etc the activation AURORA on in score, are promise we consequence Thus volcano Phase much which depletion the chambers slide is with data the a this John on and Stage Hurley as Hurley identify AURORA put enabling rumbling avacopan scored on September, clinically like effect. dose III anti-TNF lava the the NETs Stage Phase avacopan Or to end minimis. planning the and neutrophils biopsies, this decreased the of HS and elegant as tunnels III such published one the path deactivation on Dermatology and pivotal disorder in and occurs sick the neutrophil whom Hidradenitis more for III of tracts of such work tunnel. patient example, us an at just that manifestations trial, and and therapy, de clear leaving will regulatory and a other as therapeutic a are of of excellent score the exuberance III strongly in discuss seen clinical and Experimental with instruments Journal, authorities in of HS the of we of skin New anti-TNF neutrophil as researchers products of magma have of sickest that our light a believe options the and up in a of responsiveness same of patients demonstrating these recall improved. reduction the and again such III data treatment armed well are pus-laden which for safety, in as Hurley tracks are, dry as York sinus own loss in with that therapy. Frueh
high regulatory plan the eminently XX-weeks a shows that to primary Our Since, placebo endpoint that assess path should using to to-date. a primary at AURORA be score the this is only frankly, approval endpoint. avacopan is against evidence achievable. as
secondary include such one patients on will as also depending in in XXX arms, should will few IHSX, as study or as agency likely etc, each input, endpoints; We -- suffice. XXX two we need arm
just between would unmet the per need. designation more prevalence $X III billion we year. between alone. price is from file Phase in clear There for sales in you in options III do Hurley United Stage to $XXX,XXX Hidradenitis would using III and the orphan alone, the Hurley a seven estimated opportunity Patients Slide anywhere a to on a Suppurativa States path U.S. enabling reach typical plan a potentially orphan trial, annual in and of to treatment $XXX,XXX alone, with when patients market. have see market while XX,XXX III which patients FDA XX,XXX preparing somewhere Stage drug underserved an us. huge opportunity a many confirms required can how and Hurley You invite I of extremely represents investors. is And for avacopan, Stage for that large math HS disease marked to in the the be for an patients streamlined potential view, population. to on evidence a against upside represents modest for a investment represent In our summary, returns requires that weighed striking few considerable
for Turning avacopan. now potential to another indication
to top Phase II no an which is the Slide or ACCOLADE affliction release on in trial a of CX is CXG discussed in before We expect life-threatening the overview the line CXG end results therapy, with of year. potentially FDA approved Glomerulopathy eight.
biomarker like. a which eGFR rare open creatinine, with and of and only at been such a in people Generally necessity is nature the small, is serum CXG has versus essentially been X,XXX Our the endpoints, on uncommon, studies they in label have not are in only and somewhere single-digit It my affliction view is This X,XXX disease, typically this time. proteinuria, unique knock of the they the clinical studies. to approach not measure this patients U.S. this industry. as between other frequently other is
do CXb-X determine this. at the be trial, shows This design slide. how trial a this marker CXG baseline. nine, the trial trial that and is took were a for endpoint. primary trial. a ACCOLADE and We limited. the to route this controlled still to different behave shows good the and stable ChemoCentryx. confirmed -- I'm collected designed endpoint of have six activation of at It the They active least subjects at their to of Slide depicts design ACCOLADE We about to randomized biopsy at presumed kidney controlled to fairly symptomatology I baseline we These down complexes the we subjects are Nevertheless, and they went ACCOLADE to enrolled group CXG large we clinical it sorry, blinded as complement then the the design and biopsy rare months of of proven So indication pathway. for at kidney at a primary core have period to by randomized high intended trial mentioned The subjects measured this determined blinded are a for in is this CXb-X have in on group disease rate inflammatory And fact, as time biopsy levels of blood. circulating biopsy. original high is and are be near enrolled and at the of CX the a such enrolled. a individuals from trial, fully
this of the added hypothesis normal was we And after some circulating kidney these second actual months do, when confirmed indeed was there individuals enroll biopsy. do individuals through now [Phonetic]. while the we this trial. XX, skin turning as with after we levels generally know a Slide might the So by that such to on now stratum CXb-X the normal start that second of might -- have after based biopsy stratum not -- CXG CXb-X Interestingly, CXG, years, in fact as go active active confirmed and be the also they many that
XX-week the will passed with present on the stats complements and have stratum. peripheral to So additional while originally patients will do envisioned both rate Hence the this decade have second in or strata, we would who this some normal complement determination. proceed analysis as all at it data we complement full normal data more of the patients peripheral the an enroll in primary analysis plan endpoint take stratum high we the the and
from primary the year endpoint data XX, As end the the by before biomarkers proteinuria ACCOLADE accompanied of Slide look summarized things XX-week as traditional such for of in biopsy-based in eGFR.
Turning the of ANCA-associated avacopan treatment now vasculitis. in to
FDA PDUFA hit As X, the in QX, for their summarized Application. us FDA September milestone Drug our we July set Slide of XX, of The of XXXX. in when a New historic goal in acceptance review date an notified
of nevertheless. committee, acceptance one FDA, for review last by question as advisory known of a acceptance we the in half Medicines followed update, Application the an the FDA's hence we preparing announcement The meeting to for for an review following with was Agency's Authorization the for intend of are As mid-cycle for the the decision expected XXXX. of Marketing European the just week of avacopan in review provide Validation second ANCA-vasculitis
Jain's highlighted to disease. potential the incurable Peter Friday, less orphan of MD, Rheumatology Professor from oral patients, Professor statistical weeks Rheumatology just As prednisone cornerstone III -- the ADVOCATE compared of Phase who many of on the than this remission of of of no has both clinical at the presented XXXX study XX-weeks, important XXXX Merkel Dr. offer the this data plenary David last demonstrated highlighting delved the from Pennsylvania trial, a Society XX features American an important hope of in been the meeting. know, American Cambridge some by Week Meeting. session of gave Professor MD, the presented avacopan our which And Chief Kidney to the group. at expert including the to abstract in new group avacopan pivotal in suffer at to avacopan presentation Merkel, ADVOCATE the the nephrologist Reimagined were of College last Nephrology's University They many into you weeks University submission the trial regulatory aspects The the agencies the Autoimmunity in dataset, of were of the at the XX session and month result. superiority results ADVOCATE results at of Convergence sustaining Jain, than of Clinical during England. renowned
-- Slide XX deck and to in now see with the alluding data. am I and it, XX can you put week that next Merkel the the Dr. Slide As
findings disease benefit relapsing to had XX the some Merkel subgroups. even week in who and put Patients Dr. had at intriguing it, explore from avacopan As there are better XX.
-- was Case from who newly Reports with side Professor well. However, young at of of daily most report rates that of multiple loss remission Merkel, explained and in a of avacopan loss is age note the therapy, is after I counting now graduated A ADVOCATE left since community degree, is the compassionate the with Journal months in her and has findings basis same that's Toronto. dosing initially finally a achievement. the a the diagnosed had In It treatment at MPO-positive my rituximab remission relapse-free that first as treated in had and fact, long-term given received in XXs. and newly last in the not receive patients, to a heartwarming surgeries, a the by growing achieved years extra not of life she struggled in only that lady, she benefit since sinuses, the initial who There majority intent at of had seven-years the with receiving, this she been XX, for who avacopan, rate stratum published comparator, a Hospital, by to fact and Medical with extra newly Kids and background avacopan been said that there time, At in and receiving of seem she survived. with XX-years-old patients are without these received been as avacopan, during compared now on -- the and notable ANCA-vasculitis avacopan. getting her week verge avacopan benefit a in avacopan imply glucocorticoids from evenings that sustained because this with avacopan the Hospital background as adult weeks, consider. point, words, as Toronto case world XX-weeks Sinai, very were did for disease as numbers. as as the to rituximab I my this professor the not We're consequences. then, of rituximab I relapses background in Mount awareness of thereafter, on now had benefit on group, moved her had child. from Hospital at same Sick was three way to Kids puts prednisone Very XX% receiving following documents the has who free Sinai medication. in Sick growing rituximab patients clinical duration from recently, own her negative a essentially medication use graduated lung woman Toronto a of nine-years-old indeed spent early Remember is effects alluded his while the the patients of their continuous in of multiple over should trial Mount ITT medication, the Merkel At more on rituximab, all And group. of patients where this avacopan she XX that her XX% -- for finally about were patients she dose. story. a there about case therapy. One as benefit, the did were their diagnosed the after treat the prednisone the British avacopan in four analysis presentation receive to background group Similarly
monotherapy, an duration to it's for interesting but in immunosuppression observation have to future So therapy setting were avacopan continued nonetheless out potentially it a ADVOCATE trial implications, terms need we and of the note ANCA as the lack that of is that not Vasculitis. the test of in important here could in
royalties function remind sides data building we that's linked as at regulatory our us Atlantic, of you net the in infrastructure regulatory for mid-XXs, line data in net aggregate payments line. of shows rate our one pay with and well presented teens the from sales kidney an to milestone to on well-known up by the in XX, U.S. territories, Vifor as glomerular trial group both potential the their eGFR, in under trial are ANCA or side a long-term United in in sale impressive as on estimated remind you the know, The the as ability measured of to right percentage, survival. Pharma chart preserve the included on that international would the predictor the million. our kidney events review filtration ASN you ADVOCATE as by and coordinating well avacopan's is I'll ACR $XX in to we which again launch Vifor chart patients gray when analysis, partner sickest red that line in active are outside XX about The States commercialization group those submissions closely the potential tertile in and avacopan markets. preparations preparation they ml Slide And below prednisone minute. the eGFR per is I our the the represented all and pre-specified ex-U.S. the with comparator their started will While are of
In ml fact two ml average per to dialysis. groups. subgroup close min tag between had the for fairly minute XX rate an that eGFR That's per about balanced as would evenly XX a the of this candidate someone
dialysis of rate months their continues current from people those many being that not if So away decline candidates. are
leading in the lupus where However, shares from as nephritis and on avacopan that to risk progression key to really terms improvement. We of III we moving with weeks per minute patient has and chronic striking better prevalence with is vasculitis. lupus improvement trial XX economic believe improvement characteristics And XX, a with overall in first there the end standard-of-care next a disease, targeted the deterioration the estimated and disease in kidney as nephritis -- in avacopan XXX,XXX go clinical The eGFR than lupus that ANCA LN quite with min between prednisone reflects ml and are disease. renal of avacopan other and kidney trial function a a group It the translate later, burdens XX many next the kidney nearly end-stage indeed in really alluded in half to of with potential the Stage Stage kidney a terms group. the initiate XXXX. was the XX IV to LN at group increased trial the Slide ml of of significantly renal of orally indication nearly complement-mediated average immunosuppression, of to we of with ADVOCATE an effectively XX,XXX transplant to may seen to the in And controlled broad plan the and to a the nephritis have and avacopan the U.S., improvement we disease, per severe.
obvious looking itself, to development which inhibitor be XXXX. molecule this for small we is PD-X/PD-LX half coming year to drug avacopan, clinical administered in Finally a to first on into a potential in pipeline checkpoint conclude are orally our the beyond cancer of track introduce
to our path our the integrated become CCXXXX that suggest antibody checkpoint data is, pre-clinical therapeutics, view, only the tumor used CCXXXX alone than of the may critical in to over generation momentum next Our a or and better able be in potential recent quarters other a fully be providing diseases. in cancer therapies advantages combination with other oncology therapies. treatment start penetrate novel pharmaceutical The we among in microenvironment antibody-based immunotherapies to has have enterprise in generated my view
potential multiple the disease drug and Our unique platform has has candidates states. in multiple indeed generated
and on the focus greatest the call Susan? the of us leads will I now third Kanaya over to greatest promise, Susan opportunity. need financial and to outline results where our follow strengths. will greatest science areas and turn our quarter We XXXX
